Cretostimogene + Pembrolizumab
BCG-unresponsive NMIBC (CIS-containing)
Phase 2Active (CORE-001)
Key Facts
Indication
BCG-unresponsive NMIBC (CIS-containing)
Phase
Phase 2
Status
Active (CORE-001)
Company
About CG Oncology
CG Oncology is a late-stage biopharma company with a mission to deliver innovative, bladder-sparing immunotherapies for patients with non-muscle invasive bladder cancer (NMIBC). Its lead asset, cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy, has garnered FDA Fast Track and Breakthrough Therapy designations and is in a pivotal Phase 3 program. The company's strategy is intensely focused on successfully commercializing this potential backbone therapy in a significant market with limited effective options for BCG-unresponsive patients.
View full company profile